Skip to content

A Real World Study Based on NGS (TRUMPRWS)

TRUMPRWS: A Non-interventional Study on Genetic Variants and Its Clinical Relevance in Chinese Patients With Advanced NSCLC (TRUMPRWS)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03605602
Acronym
TRUMPRWS
Enrollment
2700
Registered
2018-07-30
Start date
2018-08-01
Completion date
2024-12-30
Last updated
2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Carcinoma of Lung, TNM Stage 4

Brief summary

This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner.

Detailed description

This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner. The eligible patients will be recruited after NGS analysis for tumor tissue and the inform-consent is obtained. The study required information will be collected (every 3 months).

Interventions

No drug intervention or tissue sampling will be included in this study.

Sponsors

Guangdong Association of Clinical Trials
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients must be ≥20 years of age. 2. Provision of fully informed consent prior to any study specific procedures. 3. Histologically or cytologically confirmed, unresectable stage IIIB or stage IV NSCLC. 4. Genetic variants of tumor tissue detected by NGS.

Exclusion criteria

None.

Design outcomes

Primary

MeasureTime frameDescription
Clinical relevance between genomic profiling and overall survival[ Time Frame: From registration onto that step until death, or censored at the date of last contact, assessed up to 3 years]Kaplan-meier analysis of overall survival based on different genetic alteration

Secondary

MeasureTime frameDescription
The characteristics of genomic variation and dynamic changes during different anti-tumor treatment24 monthsSubtypes, incidence and dynamic changes of genomic variants during treatment process.

Countries

China

Contacts

Primary ContactYi-Long Wu, Professor
syylwu@live.cn+86 20 83827812
Backup ContactXiao-Yan Bai, Dr.
799836599@qq.com+8615347435499

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026